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Diabetes is a major risk factor for the development of athero-
sclerosis, but the mechanism by which hyperglycemia acceler-
ates lesion development is not well defined. Insulin and insulin-
like growth factor I (IGF-I) signal through the scaffold protein
insulin receptor substrate 1 (IRS-1). In diabetes, IRS-1 is down-
regulated, and cells become resistant to insulin. Under these
conditions, the IGF-I receptor signals through an alternate scaf-
fold protein, SHPS-1, resulting in pathophysiologic stimulation
of vascular smooth muscle cell (VSMC) migration and prolifer-
ation. These studies were undertaken to determine whether
IRS-1 is functioning constitutively to maintain VSMCs in their
differentiated state and, thereby, inhibit aberrant signaling.
Here we show that deletion of IRS-1 expression in VSMCs in non-
diabetic mice results in dedifferentiation, SHPS-1 activation, and
aberrant signaling and that these changes parallel those that occur
inresponse tohyperglycemia.Themiceshowedenhancedsensitiv-
ity to IGF-I stimulation of VSMC proliferation and a hyperprolif-
erative response to vascular injury. KLF4, a transcription factor
that induces VSMC dedifferentiation, was up-regulated in IRS-
1/ mice, and the differentiation inducer myocardin was unde-
tectable. Importantly, these changes were replicated in wild-type
mice during hyperglycemia. These findings illuminate a new func-
tion of IRS-1: that of maintaining cells in their normal, differenti-
atedstate.BecauseIRS-1isdown-regulatedinstatesofinsulinresis-
tance that occur in response to metabolic stresses such as obesity
and cytokine stimulation, the findings provide a mechanism for
understanding how patients withmetabolic stress and/or diabetes
are predisposed to developing vascular complications.
Diabetes is a major predisposing factor for the development
of atherosclerosis. The diabetes control complications trial
showed that patients with type 1 diabetes who maintained a
hemoglobin A-1 C value 1.2% lower than control subjects for 7
years had a significantly reduced rate of vascular disease events
during the 20-year follow-up period (1). Similarly the United
Kingdomprospective trial demonstrated a significant benefit of
lowering glucose in type 2 diabetics on cardiovascular risk (2).
Despite intense analysis, the molecular mechanism by which
glucose lowering results in a clinical benefit has remained
poorly defined. Insulin and insulin-like growth factor I (IGF-I)2
signal through a scaffold protein termed insulin receptor sub-
strate 1 (IRS-1) (3). The insulin and IGF-I receptor tyrosine
kinases directly phosphorylate IRS-1, and these phosphoty-
rosines recruit the p85 subunit of PI3K and Grb-2, thereby
activating the PI3K andMAPK pathways (4). In differentiated
cells, these IRS-1-linked signaling cascades promote glucose
influx; glycogen, lipid, and protein synthesis; aswell as changes in
gene expression (5). Under normal physiologic conditions, both
insulin and IGF-I stimulate differentiated cell functions through
IRS-1 activation (6–7). In response to hyperglycemia, proinflam-
matory cytokines, or nutrient excess, IRS-1 is down-regulated in
multiple tissues, and insulin signaling is impaired (8–9). In cell
types that are capableof undergoingdedifferentiation, suchas vas-
cular smooth muscle cells (VSMCs) and endothelial cells, IGF-I
utilizes an alternative mechanism to stimulate PI3K and MAPK
activation (10). IGF-I stimulates tyrosine phosphorylation of the
scaffolding protein Src homology 2 domain-containing protein
tyrosine phosphatase substrate 1 (SHPS-1), which recruits signal-
ing elements that activate both the PI3K and MAPK pathways,
leading to enhanced cell migration and proliferation (11). In con-
trast, under the samehyperglycemic conditions, overexpressionof
IRS-1 down-regulates SHPS-1 expression, thereby restoring sig-
naling through IRS-1, which inhibits these pathophysiologic
changes (12).DedifferentiationofVSMCshasbeen implicatedas a
major event in atherosclerotic lesion formation (13). Several sig-
nalingeventsbywhichexternal stimuli suchashyperlipidemiaand
cytokine expression control differentiation have been reported,
but the changes in signaling that lead to dedifferentiation of
VSMCsduring hyperglycemia have not been characterized. Based
on those observations, we investigated whether IRS-1-mediated
signaling was required to maintain VSMC differentiation and
whether decreased expression of IRS-1 led to dedifferentiation
and altered sensitivity to stimulation of cell proliferation.
* This work was supported by National Institutes of Health Grants AG02331
and EY021943. The authors declare that they have no conflicts of interest
with the contents of this article. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institutes of Health.
1 To whom correspondence should be addressed: CB#7170, 8024 Burnett-
Womack, Div. of Endocrinology, University of North Carolina, Chapel
Hill, NC 27599-7170. Tel.: 919-966-4735; Fax: 919-966-6025; E-mail:
david_clemmons@med.unc.edu.
2 The abbreviations usedare: IGF, insulin-like growth factor; IRS, insulin recep-
tor substrate; VSMC, vascular smooth muscle cell; AKT, protein kinase B;
PCNA, proliferating cell nuclear antigen; UNC, University of North Carolina.
crossmark
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 292, NO. 5, pp. 2009–2020, February 3, 2017
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
FEBRUARY 3, 2017•VOLUME 292•NUMBER 5 JOURNAL OF BIOLOGICAL CHEMISTRY 2009
Results
To determine the effect of loss of expression of IRS-1, we
preparedmice in which expression had been selectively deleted
in VSMCs. As shown in Fig. 1, IRS-1 expression was eliminated
in VSMCs but not in the liver, kidney, heart, skeletal muscle
(Fig. 1A), or endothelium (Fig. 1B). Similarly, IRS-2 was selec-
FIGURE 1.Deletion of IRS-1 or IRS-2 expression in vascular smoothmuscle frommouse aorta. IRS-1 or IRS-2 smoothmuscle-specific knockoutmice were
generated following a procedure described under “Experimental Procedures.” A, 15-week-old IRS-1 smooth muscle-specific knockout mice were sacrificed,
and aortae as well as the organs listed were removed. Organ and tissue extracts were prepared as under “Experimental Procedures,” immunoblotted (IB) with
an anti-IRS-1 antibody, and reprobed with an anti--actin antibody. B, aortas were cleaned by removing the connective tissue and the adventitia under the
dissectingmicroscope. The cleaned aortaswere opened longitudinally, and the endothelium (Endo) was collected in the PBS by gently scrapingwith a scalpel.
The endothelia from nine aortae were pooled and then lysed using a modified radioimmunoprecipitation assay buffer. The remaining SMCs were analyzed
separately. The lysates were immunoblotted as in A. C, 15-week-old IRS-2 smoothmuscle-specific knockout mice were sacrificed, and aortic or hepatic lysates
were prepared as described under “Experimental Procedures.” The tissue lysates were immunoblotted with an anti-IRS-2 antiserum and reprobed with an
anti--actin antibody.M1 andM2 denote two representative mice. D, aortic extracts from normal wild-type (WT/ NG, n 4), diabetic wild-type (WT/ HG,
n 4), and normal IRS-1 knockout (IRS-1/NG, n 4) mice were immunoprecipitated and immunoblottedwith an anti-IRS-2 antibody. The same amount of
extractwas immunoblottedwith an anti--actin antibody to control for protein loading. The ratio value of the scanning units for IRS-2 divided by the scanning
units of corresponding -actin from the first lane (WT/ NG) was set as 1.0, and the values of other lanes were obtained from the ratio value of the
corresponding lane divided by the ratio value of the first lane. E, aortic extracts from normal wild-type (WT/ NG, n 4) and IRS-2 knockdown (IRS-2/ NG,
n 4) mice were immunoblotted with anti-IRS-1 and anti--actin antibodies. The ratio value of the scanning units for IRS-1 divided by the scanning units of
corresponding -actin from the first lane (WT/ NG) was set as 1.0, and the value of the second lane was obtained from the ratio value of the second lane
(IRS-2/ NG) divided by the ratio value of the first lane. F, aortae were removed from IRS-1 or IRS-2 smooth muscle-specific knockout mice or their wild-type
littermates, and the adventitia was removed under a dissecting microscope before weighing. G, sections of aortae fromWT or IRS-1 or IRS-2 smooth muscle-
specific knockout mice were stained with hematoxylin and eosin, and images were captured using an Olympus BX61 microscope. The aortic thickness was
measured following the procedure described under “Experimental Procedures.” H, the same sections as in Gwere stained with DAPI following the procedure
described under “Experimental Procedures.” The total nuclei were counted in each group. ***, p 0.001; *, p 0.05; significant differences between mouse
genotypes. NS, no significant difference between two treatments. Error bars denote the standard deviation.
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tively deleted in the aorta but not in the liver (Fig. 1C). Further-
more, no compensatory increase in IRS-2 expression was
detected in the aortas of IRS-1/mice and vice versa (Fig. 1,D
and E). There was no difference in body weight or organ size
among the groups. However, smooth muscle-specific deletion
of IRS-1 or IRS-2 resulted in a significant reduction in the
weight of the aorta compared with control animals, and the
effect of IRS-1 deletion was significantly greater than deleting
IRS-2 (Fig. 1F). Similar results were obtained when the aortic
wall thickness (e.g. control, 97 3; IRS-1/, 89 2; IRS-2/,
92  3 m) and total nuclei (e.g. control, 393  32; IRS-1/,
303 33; IRS-2/, 334 30) in the aortic ring sections were
analyzed (Fig. 1,G andH). These results are consistent with the
known effects of IRS-1 and IRS-2 in mediating fetal growth (4).
Our prior studies have shown that, in response to hyper-
glycemia and IRS-1 down-regulation, the transmembrane
protein SHPS-1 is up-regulated and functions to transduce
IGF-I signaling (10–11). The IGF-I receptor phosphorylates
SHPS-1, which forms a scaffold for signaling complex localiza-
tion, and this complexmediates IGF-I actions inVSMCsduring
hyperglycemia (10, 12). Therefore, we analyzed SHPS-1 com-
plex activation in the different settings. Our results showed that
IGF-I stimulatedamajor increase inSHPS-1 tyrosinephosphor-
ylation in aortae from IRS-1 VSMC knockout non-diabetic
mice, and wild-type animals that had been made diabetic
showed a similar response, whereas normal control mice
showed no change in SHPS-1 phosphorylation (Fig. 2A). This
change was specific for IRS-1 because IRS-2 VSMC knockout
animals showed no SHPS-1 phosphorylation response. In con-
trast, IRS-1 tyrosine phosphorylation in response to IGF-I
could only be detected in normal wild-type and IRS-2 knockout
animals (Fig. 2B). There was minimal IRS-2 protein, and no
IRS-2 tyrosine phosphorylation was detected in control, dia-
betic, wild-type animals or IRS-1 knockout animals (Fig. 2C).
This signaling switch was associated with enhanced down-
stream signaling responses.When the four groups ofmice were
compared, IGF-I induced 7.5  0.8-fold and 9.3  0.7-fold
increases in protein kinase B (AKT) phosphorylation in nor-
moglycemic IRS-1/ and diabetic (IRS-1/) animals, respec-
tively, whereas control and IRS-2/ animals showed minimal
changes (Fig. 2,D andE).WhenMAPKactivationwas analyzed,
there were 7.0  0.8-fold and 2.7  0.2-fold increases in IRS-
1/ and IRS-1/ diabetic mice, respectively, and no increase
in MAPK activation in IRS-2/ or control animals (Fig. 2, D
and E). SHPS-1-mediated activation of downstream signaling
requires recruitment of SHP-2 to the phosphotyrosines on
SHPS-1 (12). SHP-2 recruitment results in assembly of a signal-
ing complex composed of Src, p52 Shc, and Grb-2, which sub-
sequently activatesMAPKandAKT (12). Therefore, to confirm
that the changes in downstream signaling that occurred in the
IRS-1/ mice were mediated through SHPS-1, we utilized a
cell-permeable peptide that disrupts SHP-2/SHPS-1 associa-
tion (11). The peptide significantly diminished SHP-2 recruit-
ment in diabetic (IRS-1/) and non-diabetic IRS-1/ mice
(Fig. 3A). Importantly, it also inhibited IGF-I induction of AKT
and MAPK activation (Fig. 3B).
Next we determined the significance of these changes in sig-
naling for cellular replication. IGF-I induced no change in rep-
lication in aortae obtained from control animals; however, fol-
lowing IRS-1 deletion, there was a 2.0  0.3-fold increase in
Ki67 labeling that was comparable with the 1.6  0.1-fold
change that occurred in wild-type diabetic animals (Fig. 4).
However, in IRS-2 knockout animals, this increase could only
be detected in diabetic animals, and the magnitude of the
increase was similar to wild-type animals (1.8 0.6-fold versus
1.6 0.1-fold increases). VSMCs in adult animals are capable of
undergoing dedifferentiation, and this results in a hyperprolif-
erative response to growth stimuli. Therefore, we determined
whether IRS-1 knockdown was associated with a change in
VSMC differentiation. As shown in Fig. 5A, the transcription
factor Kruppel-like factor 4 (KLF-4), which inhibits the expres-
sion of genes that stimulate smooth muscle cell differentiation,
was significantly increased in the IRS-1/mice. This increase
was also noted in diabetic animals, but there was no change in
wild-type non-diabetic or IRS-2/ animals. This change was
associated with amarked decrease in the expression ofmyocar-
din, a protein whose expression is required for VSMC differen-
tiation (13) (Fig. 5A), and SM22, amarker of smoothmuscle cell
differentiation (Fig. 5D). Similar to wild-type animals, these
changes were only detected in the diabetic animals but not in
non-diabetic animals with IRS-2 deletion (Fig. 5, B and E).
Importantly, these changes could be reversed using SHPS-1/
SHP-2-disrupting peptide in diabetic wild-type mice and IRS-
1/ mice; that is, KLF4 expression was inhibited, and myo-
cardin and SM22were stimulated in diabetic and IRS-1/ ani-
mals (Fig. 5, C and F). This finding strengthens the conclusion
that the SHPS-1 signaling pathway predominated under these
conditions.
To determine the functional consequences of decreased
IRS-1 expression andVSMCdedifferentiation, the three groups
of mice were wounded, and VSMC proliferation was deter-
mined. There was a major increase in arterial wall thickness in
femoral arteries from IRS-1/ animals (Fig. 6A). Quantitative
analysis showed a 4.7 0.9-fold increase in IRS-1/mice and
a 6.6 1.1-fold change in diabetic mice compared with a 2.4
0.6-fold change in control animals. To determine whether this
change was in part due to increased proliferation of VSMCs,
Ki67 labeling and -actin were analyzed. There was a 46.3%
7.4% increase in IRS-1/mice and a 50.3% 6.0% increase in
diabetic animals (Fig. 6B), whereas this changewas significantly
less (e.g. 15.0% 5.2%) in control animals. Biochemical analy-
ses verified that KLF4 expression was markedly up-regulated
following wounding, and myocardin expression was undetect-
able in the IRS-1/ and diabetic mice (Fig. 7A). In contrast,
there was no change in control animals. Similarly, MAPK and
AKT phosphorylation were markedly enhanced in IRS-1/
mice and the diabetic (IRS-1/) animals but changed only
minimally in the non-diabetic controls (Fig. 7B). To determine
whether these changes might affect vascular function, several
markers, such as SM22, -actin, and proliferating cell nuclear
antigen (PCNA), were analyzed. The results showed that
wounding treatment induced PCNA in diabetic wild-type and
non-diabetic IRS-1/ mice, whereas SM22 and -actin ex-
pression were remarkably reduced (Fig. 7C).
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Discussion
During normoglycemia, adult VSMCs remain differentiated
and do not proliferate. Under these conditions, IRS-1 mediates
normal physiologic responses following insulin or IGF-I stim-
ulation, including glucose transport, protein synthesis, and
inhibition of apoptosis (3). In contrast, during hyperglycemia or
insulin-resistant states, IRS-1 is down-regulated (8–10). In
cultured VSMCs exposed to high glucose, IGF-I downstream
signaling is dysregulated and mediated through the scaffold-
ing protein SHPS-1 (11–12). Overexpression of IRS-1 under
these conditions inhibits SHPS-1 tyrosine phosphorylation in
response to IGF-I, and this is associated with attenuated VSMC
migration and proliferation (12). This study was undertaken to
determine whether IRS-1 functions constitutively in a cell-au-
tonomous manner to inhibit these aberrant responses under
normoglycemic conditions in vivo. The findings demonstrate
unequivocally that this signaling switch occurs in intact arteries
in mice following deletion of IRS-1 expression. Specifically, in
VSMCs, IRS-1 deletion resulted in enhancement of the ability
of IGF-I to stimulate SHPS-1 tyrosine phosphorylation during
normoglycemia. This function was cell-autonomous and not
dependent on deletion of IRS-1 expression in other vascular cell
types, such as endothelium. This up-regulation of SHPS-1 tyro-
sine phosphorylation during normoglycemia resulted in signif-
icant enhancement of AKT andMAPKphosphorylation as well
as cell proliferation. Of greater importance is that knockdown
of IRS-1 led to increased expression of the dedifferentiation-
associated transcription factor KLF-4 and down-regulation of
myocardin and SM22, two important stimuli of VSMC differ-
entiation. Therefore, we conclude that IRS-1 expression is nec-
essary to maintain VSMCs in their normal, differentiated state.
The loss of IRS-1 results in dedifferentiation that is accompa-
nied by aberrant signaling through SHPS-1 and enhancement
FIGURE2.Smoothmuscle-specific knockoutof IRS-1butnot IRS-2 enhances IGF-I signaling in aortae fromnormalmice.Aortae fromwild-typemice (WT
NG), diabetic wild-typemice (WTHG), non-diabetic IRS-1 (IRS-1/NG) or IRS-2 (IRS-2/NG) VSMC knockoutmice that had been injectedwith IGF-I () or PBS
() (Ctrl) were prepared as under “Experimental Procedures.”A, aortic lysateswere immunoprecipitated (IP) with an anti-SHPS-1 antibody and immunoblotted
(IB) with anti-Tyr(P)-99. The blots were reprobed with an anti-SHPS-1 antibody as a loading control. The value of each column is the ratio of the mean S.D.
value of the scanning units for pSHPS-1 divided by the scanning units of total SHPS-1. B and C, aortic lysates were immunoprecipitated with an anti-Tyr(P)-99
antibody and immunoblotted with anti-IRS-1 (B) or IRS-2 (C). The same amount of lysate was analyzed using an anti-IRS-1 (B) or IRS-2 (C) antibody as a loading
control.D and E, aortic lysates were immunoblottedwith anti-pAKT (Ser-473) or anti-pErk1/2 and reprobedwith an anti--actin antibody as a loading control.
The value of each bar is the ratio of themean S.D. of the scanning units for pAKT or pErk1/2 divided by the scanning units of corresponding -actin band. *,
p 0.05; **, p 0.01; significant differences between IGF-I treatment and the basal level. Each experimental data point represents themean S.D. obtained
from two replicates of three mice per treatment.
FIGURE 3. Disruption of SHPS-1 signaling complex formation prevents
enhanced IGF-I-dependent MAPK and AKT activation. A, aortic lysates
from diabetic wild-type mice (WT HG) and normal IRS-1 knockout mice (IRS-
1/ NG) that had been treated with a control peptide (CP) or a SHPS-1/SHP-
2-disrupting peptide (AP) were immunoprecipitated (IP) with an anti-SHPS-1
antibody and immunoblotted (IB) with an anti-SHP-2 antibody. The same
amount of each aortic lysate was immunoblotted with an anti-SHPS-1 anti-
body as a loading control. Scanning densitometry values obtained from of
the aortic extracts from three mice in two separate experiments showed a
5.8  0.9-fold increase in wild-type diabetic mice exposed to the control
peptide and a 1.6 0.3-fold (p 0.01) change with the disrupting peptide.
The increaseswere 6.40.7-fold and1.40.2-fold (p0.01), respectively, in
IRS-1/ mice. B, the aortic extracts were immunoblotted with anti-pAKT
(Ser-473) and pErk1/2 antibodies. The blots were reprobed with an anti--
actin antibody to control for loading. The increases AKT activationwere 9.5
1.7-fold and 1.7 0.2-fold (p 0.001) inwild-type diabetic and 9.1 1.5-fold
compared with 2.0  0.3-fold (p  0.01) in IRS-1/ mice. The changes in
MAPK were 6.0 1.0-fold and 1.2 0.2-fold (p 0.01) in diabetic wild-type
mice and 7.9 1.6-fold compared with 1.3 0.3-fold (p 0.01) in IRS-1/
mice.
FIGURE4.Smoothmuscle-specific knockoutof IRS-1enhances IGF-I-stim-
ulated VSMC replication in aortae fromnormalmice.NormalWT (n 12),
diabetic WT (n 12), normal IRS-1 knockout (Normal IRS-1/, n 12), nor-
mal IRS-2 knockout (Normal IRS-2/, n 8), or diabetic IRS-2 knockout (Dia-
betic IRS-2/, n 8) mice were injected with IGF-I or PBS i.p. twice (24 h and
15 min) before sacrifice. Paraffin-embedded sections were stained with anti-
Ki67 antibody and DAPI following the procedures described under “Experi-
mental Procedures,” and the number of proliferating cells and total nuclei in
the each section (total 30 sections) were counted and expressed as the per-
centage of Ki67-positive nuclei. The mean values  S.D. from 6 mice/treat-
ment group (3 sections measured/mouse) are shown graphically, and repre-
sentative images are also shown. ***, p  0.001; **, p  0.01; significant
differences when the two treatments were compared. NS, no significant dif-
ference between two treatments. Ctrl, control.
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FIGURE 5. Smoothmuscle-specific knockout of IRS-1 but not IRS-2 stimulates the dedifferentiation of aortic smoothmuscle cells. A, B,D, and E, aortae
fromnormalwild-typemice (WT/NG), diabeticwild-typemice (WT/HG), normal IRS-1 knockoutmice (IRS-1/NG), IRS-2 knockoutmice (IRS-2/NG), or
diabetic IRS-2 knockout mice (IRS-2/ HG) were prepared following the procedure described under “Experimental Procedures.” The lysates were immuno-
blotted (IB) with anti-KLF4, anti-myocardin (A and B) or anti-SM22 antibody (D and E). The blots were reprobed with an anti--actin antibody as a loading
control. The value of each column is the ratio of themean S.D. value of the scanning units obtained from6mice/group for KLF4,myocardin, or SM22 divided
by the scanning units of corresponding -actin, respectively. *, p 0.05; **, p 0.01; ***, p 0.001; significant differences between twomouse types. C and
F, aortic lysates fromdiabeticwild-typemice (WT/HG) or non-diabetic IRS-1 knockoutmice (IRS-1/NG) treatedwith SHPS-1/SHP2-disrupting peptide (AP)
or a control peptide (CP) for 5 days were immunoblotted with anti-KLF4, anti-myocardin (C), or anti-SM22 antibody (F). The blots were reprobed with an
anti--actin antibody as a loading control.M1 andM2 denote two representative mice for each group.
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of VSMC proliferation in response to IGF-I or vascular injury
(Fig. 8).
In addition to SHPS-1 activation, we investigated the possi-
bility that up-regulation of IRS-2 could compensate for loss of
IRS-1. However, the results clearly show that, following IRS-1
deletion or induction of diabetes, there is no increase in IRS-2
and that deletion of IRS-2 does not induce SHPS-1 activation in
the aorta. Therefore, we conclude that the loss of IRS-1 does not
induce IRS-2 and that the switch in signaling that occurs with
hyperglycemia from IRS-1 to SHPS-1 is IRS-2-independent.
IRS-1 is down-regulated in multiple cell types in response to
hyperglycemia, including VSMCs (11), skeletal muscle (14),
endothelium (15), pre-adipocytes (16), hepatocytes (16), and
cardiomyocytes (17). Severalmechanisms have been postulated
to mediate this change, including serine phosphorylation of
IRS-1 (18), direct proteolytic degradation (19), and ubiquitina-
tion with targeting to proteasomes (20). Multiple serine/threo-
nine kinases, including JNK, mechanistic target of rapamycin
(mTOR), MAPK, and several protein kinase C isoenzymes that
phosphorylate IRS-1 are activated in response to hyperglycemia
(21–22). Cytokine activation of the NF-B pathway (23), dys-
lipidemia (24), and hormones that stimulate endothelial dys-
function, such as angiotensin II (25) and aldosterone (26),
induce IRS-1 down-regulation, and this is a mechanism by
which these factors confer insulin resistance. Whether each of
these factors can induce SHPS-1 activation has not been
reported, but a recent study showed that TNF stimulation of
skeletal muscle activated SHPS-1 expression and down-regu-
lated IRS-1 (23). In that model, knockdown of SHPS-1 restored
insulin signaling and IRS-1 tyrosine phosphorylation. This sug-
gests that there is a dynamic interplay between IRS-1 and
SHPS-1 signaling to maintain insulin sensitivity and that dys-
FIGURE 6. Smooth muscle-specific knockout of IRS-1 enhances femoral arterial cell proliferation after injury. Femoral arterial sections after injury or
sham treatment from normal wild-type, diabetic wild-type, and normal IRS-1/mice were prepared following a procedure described under “Experimental
Procedures.” A, the sections were stained with Masson trichome elastin stain, and images were captured and analyzed as under “Experimental Procedures.”
Representative cross-sections are shown. The value of each column is the mean value S.D. obtained from 12 mice from each group. B, the sections were
stainedwith anti-Ki67 andanti--actin antibodies andDAPI followingaproceduredescribedunder “Experimental Procedures.” The valueof each column is the
mean value S.D. of the percentage increase of Ki67-positive nuclei after injury above the sham treatment value for eachmouse group (n 12). **, p 0.01;
*, p 0.05; significant differences when the two treatments or twomouse types were compared. NS, no significant difference. Error bars denote the standard
deviation.
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regulation of insulin/IRS-1 signaling in response to cytokines is
mediated through SHPS-1.
Unlike IGF-I, peptide growth factors, such as PDGF, that are
potent stimuli of VSMC proliferation down-regulate IRS-1
expression even during normoglycemia (27). Similarly, loss of
insulin receptor signaling through geneticmanipulation results
in decreased IRS-1 activation and leads to enhanced serum
stimulation of smooth muscle cell proliferation (28). A prior
study demonstrated that mice that were globally heterozygous
for IRS-1 were more sensitive to vascular dysfunction in the
presence of genetically induced lipoprotein excess (29). How-
ever, in thosemice, the change in IRS-1 was present inmultiple
cell types that contribute to atherogenesis, including endothe-
lial cells and macrophages as well as smooth muscle cells. In
contrast, our study clearly demonstrates that a cell-autono-
mous reduction of IRS-1 results in markedly altered intracellu-
lar signaling, VSMC dedifferentiation, and abnormal prolifera-
tion, suggesting that these changes enhance cellular sensitivity
to IGF-I stimulation by a mechanism that is independent of
changes in these other cell types.
The key finding in this study is that IRS-1 is functioning to
inhibit dedifferentiation and, thereby, maintain VSMCs in the
differentiated state. This appears to bemediated by its ability to
attenuate the expression of KLF-4, a transcription factor that
induces smoothmuscle cell dedifferentiation (30). Suppression
of KLF-4 resulted in maintenance of myocardin expression,
which is essential for smooth muscle cell differentiation (13).
Myocardin suppression may also regulate the proliferative
response to injury because myocardin expression was robust in
wild-type animals but nearly absent in IRS-1/ animals that
had a hyperproliferative response to injury, and myocardin is
known to modulate this response (31). Other variables, such as
TNF, PDGF, and oxidized LDL, that regulate VSMC differen-
tiation stimulate KLF-4 expression, thereby resulting in en-
hancement of VSMCdedifferentiation (30, 32–33). During vas-
cular injury, KLF-4 is up-regulated, and this is accompanied by
dedifferentiation (34–35). This finding was replicated in our
study, and we noted an enhanced dedifferentiation response in
the absence of IRS-1, suggesting that IRS-1 is also functioning
during injury to attenuate smooth muscle cell proliferation by
this mechanism. KLF-4 can also be induced by other athero-
genic stimuli, such oxidized phospholipids and advanced glyca-
tion end products (32–36).
Cyclosporine, which induces KLF-4 expression, also induces
smooth muscle cell dedifferentiation (37). In contrast, myocar-
din overexpression promotes VSMC differentiation and in-
creases the expression of other VSMC marker proteins (38).
Factors that inhibit myocardin expression are associated with
dedifferentiation (35). Therefore, our finding of loss of myocar-
din expression in IRS-1/mice strongly supports the conclu-
sion that loss of the ability of IRS-1 to suppress dedifferentia-
tion is mediating the abnormal growth-regulatory response.
Although this study was confined to the analysis of vascular
smooth muscle cell differentiation and growth, down-regula-
tion of IRS-1 occurs in multiple cell types in the presence of
hyperglycemia (4, 14–16). This raises the possibility that IRS-1
could regulate the state of differentiation in other cell types,
such as vascular endothelium, podocytes, and pericytes, whose
differentiated functions undergo pathophysiologic changes
that lead to diabetic complications (39). Therefore, the reduc-
tion in IRS-1 that occurs in these cell types because of hypergly-
cemia or insulin resistance could lead to abnormal angiogenesis or
podocyte dysfunction (40–41). New strategies that focus onways
of controlling this dysregulation of IRS-1 expression hold promise
for developing medical treatments that reverse or stabilize the
development of these diabetic complications.
Experimental Procedures
Human IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Immobilon-P membranes, antibodies against
IRS-1 (catalog no. 05-1085) and SHP-2 (catalog no. 06-118)
were purchased from EMD-Millipore (Billerica, MA). Anti-
bodies against phospho-AKT (Ser-473) (catalog no. 9271) and
phospho-Erk1/2 (catalog no. 4370) were purchased from Cell
FIGURE 7. Smoothmuscle-specific knockout of IRS-1 enhances dedifferentiationof smoothmuscle cells andAKT/MAPKactivation in femoral arteries
after injury. Femoral arterial lysates after injury (W) or sham treatment (S) from normal wild-type (WT/ NG), diabetic wild-type (WT/ HG), and normal
IRS-1/ (IRS-1/NG)micewere prepared following a procedure described under “Experimental Procedures.”A, the lysateswere immunoblotted (IB) with an
anti-KLF4 or an anti-myocardin antibody, and the blots were reprobed with an anti--actin. The value of each column is the ratio of the mean value S.D. of
the scanning units for KLF4 or myocardin from 6 mice/group divided by the scanning units of corresponding -actin, respectively. B, the lysates were
immunoblotted with an anti-pAKT (Ser-473) or anti-pErk1/2 antibody and reprobed with an anti--actin. The value of each column is the ratio of the mean
value  S.D. from 6 mice/group of the scanning units for pAKT or pErk1/2 divided by the scanning units of corresponding -actin. C, the lysates were
immunoblottedwith an anti-PCNA, anti--actin, or anti-SM22 antibody. Theblotswere reprobedwith an anti--actin antibody as a loading control. *,p 0.05;
**, p 0.01; significant differences between injury and the sham treatment.
FIGURE 8. Signaling switch betweenhyperglycemia andnormoglycemia.
Duringhyperglycemia, IRS-1 is down-regulated, and a signaling complex that
includes SHP-2, p52shc, and Grb2 localizes on SHPS-1 in response to IGF-I
receptor-mediated SHPS-1 tyrosine phosphorylation. This leads toMAPK and
PI3K activation as well as specific pathophysiologic changes in vascular cell
function. During normoglycemia, IGF-I signaling is mediated via the IRS-1/
PI3K-dependent pathway, and the SHPS-1 signaling complex is not assem-
bled. An important function of IRS-1 is to maintain vascular smooth muscle
cell differentiation.
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Signaling Technology Inc. (Beverly, MA). Anti-phospho-tyro-
sine (PY99) (catalog no. sc7020), -actin (catalog no. sc32251),
and KLF-4 antibodies (catalog no. sc20691) were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti--
actin antibody (catalog no. A1978) was purchased from Sigma-
Aldrich (St. Louis, MO). Antibodies against Ki67 (catalog no.
ab66155) and SM22 (catalog no. ab10135)were purchased from
Abcam (Cambridge, MA). An anti-myocardin antibody (cata-
log no. MAB4028) was purchased from R&D Systems (Minne-
apolis, MN). An anti-PCNA antibody (catalog no. 610664) was
purchased from BD Biosciences (San Jose, CA). A rabbit anti-
IRS-2 antiserum was raised by our laboratory using a peptide,
CLNINKRADAKHKYLIALYT, linked to keyhole limpet hemo-
cyanin as an immunogen (42). A mouse anti-IRS-2 antibody was
providedbyDr.White (HarvardMedical School).Ananti-SHPS-1
antiserum was prepared as described previously (43). The horse-
radishperoxidase-conjugatedmouseanti-rabbit, goat anti-mouse,
and mouse anti-rabbit light chain-specific antibodies were pur-
chased from Jackson ImmunoResearch Laboratories (West Grove,
PA). The synthetic peptide YARAAARQARATLTYADLDM (a
SHPS-1/SHP-2-disrupting peptide) and YARAAARQARAVQ-
LYAVVSEE (a control peptide) were synthesized by the Protein
Chemistry Core Facility at the University of North Carolina at
ChapelHill.Thepurity and thesequenceswereconfirmedbymass
spectrometry. All other reagents were obtained from Sigma-Al-
drich unless otherwise stated.
Mice—All mouse experiments were approved by the Institu-
tional Animal Care and Use Committees of the University of
North Carolina at Chapel Hill. The floxed IRS-1 mice and
floxed IRS-2mice were provided byDr.MorrisWhite (Harvard
Medical School). They were created on C57BL/6 background
mice following the procedures described previously (44–45).
To generate smooth muscle-specific knockout mice, floxed
IRS-1 (IRS-1fl/fl) or floxed IRS-2 (IRS-2fl/fl) mice were crossed
with SM22-Cre mice (The Jackson Laboratory, Bar Harbor,
ME) for four generations to obtain homozygous SM22-Cre
IRS-1fl/fl or SM22-CreIRS-2fl/fl mice. Mice were maintained
at 22 °C with a 12-h light/dark cycle and given free access to
regular chow (2018 Teklad global rodent diet containing 18.6%
protein, 6.2% fat, and 3.5% crude fiber) and water. All groups of
micemaintained normal nutrient intake and growth during the
experiment.
Induction of Hyperglycemia in Mice and Preparation of Tis-
sues for Biochemical Analysis—Hyperglycemia was induced in
wild-type (IRS-1fl/fl) and smooth muscle specific IRS-2 knock-
out mice using low-dose streptozotocin (46). All mice had
serum glucose concentrations that were 250 mg/dl, and the
levels were maintained during the experiments. There were 12
mice/group (wild-type, wild-type with diabetes, and smooth
muscle-specific IRS-1 or IRS-2 knockout mice) for the bio-
chemical analyses andKi67 staining studies, respectively. There
were 16 mice/group for the femoral artery injury study and 8
mice/group for sham treatment. IGF-I (1mg/kg) (n 6) or PBS
(n  6) was administered i.p. 15 min before sacrifice for bio-
chemical analyses and 24 h and 15 min before sacrifice for
assessment of Ki67 labeling. For the SHPS-1/SHP-2-disrupting
cell signaling experiment, the disrupting peptide (2 mg/kg) and
control peptide (2 mg/kg) were injected 24 h and 1 h before
sacrifice in diabetic wild-type mice (n  12) and IRS-1 knock-
out mice (n 12), respectively. IGF-I (1 mg/kg) (n 6) or PBS
(n  6) was administered i.p. to each group of mice 15 min
before sacrifice. In experiments to assess the effect of disrupting
SHPS-1/SHP-2 on the expression of differentiation markers,
the disrupting or control peptide (2 mg/kg) was injected every
24 h for 5 days in diabetic wild-type mice (n  6) and IRS-1
knockout mice (n 6). The mice were euthanized by injection
of ketamine (100 mg/kg)/xylazine (10 mg/kg). The major
organs were cleaned by removing the connective tissues and
then weighed. The aortic endothelial cells were collected by
opening the aorta longitudinally and scraping the inside of the
vessel with a scalpel. The cells were pooled from several aortas.
For all other biochemical analyses, the aortas were opened lon-
gitudinally, the endothelial cells were removed by scraping, and
the remaining tissue was homogenized in ice-cold buffer (20
mM Tris, 150 mM sodium chloride, 2 mM EDTA, and 0.05%
Triton X-100 (pH 7.4)) using a glass tissue grinder. The lysates
were centrifuged at 13,000  g for 15 min. Protein concentra-
tions of tissue extracts were measured using a BCA assay
(Thermo Scientific, Rockford, IL). Equal amounts of protein
were used in each analysis.
Femoral Artery Injury—The procedures were performed in
the Rodent Advanced Surgical Models Core Facility at UNC
Chapel Hill. Briefly, 15-week-old mice were anesthetized with
inhaled isoflurane and placed in the supine position with their
paws fixed on the table and their lower extremities abducted
and extended. The femoral vessels were exposed by an	1-cm
longitudinal groin incision and viewed with the aid of a surgical
microscope. The segment of the saphenous artery below the
branching of the epigastric and femoral arteries was dissected
free from the adjacent nerve and vein. The distal portion of the
saphenous artery was encircled with a nylon suture, a vascular
clamp was placed proximally at the level of the inguinal liga-
ment, and a 0.010 (0.25-mm) diameter angioplasty guide wire
(Advanced Cardiovascular Systems) was introduced into the
arterial lumen through an arteriotomy made just distal to the
suture. After release of the clamp, the guide wire was advanced
to the level of the aortic bifurcation and immediately pulled
back. This process was repeated two additional times to denude
the endothelium. The guide wire was then removed, and the
arteriotomy site was ligated by tying the previously placed
suture. For sham treatment, the procedure was the same but
without guidewire treatment. The skin incisionwas closedwith
non-absorbable sutures. After surgery, mice were returned
back to animal housing and routinely monitored for 3 weeks
before being sacrificed for specimen collection.
Histology andMorphometry—The vasculaturewas cleared by
transcardial perfusion with 40 ml of PBS, followed by 40 ml of
freshly prepared 4% paraformaldehyde in PBS. Femoral arteries
were post-fixed for 24 h in 4% paraformaldehyde at 4 °C. The
sections were prepared by the UNC Histology Core Facility.
Briefly, tissue samples containing the centermost 10-mm sec-
tion distal to the inguinal ligamentwere blocked and embedded
in paraffin. Twelve adjacent 8-m sections were cut every 500
m, extending through the length of the vessel block. Serial
sections from each artery were stained with Masson trichrome
elastic stain. Images were captured using Aperio-5072 and/or
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Olympus BX61 microscopes. Images were analyzed using
ImageJ (1.47N, National Institutes of Health) by measuring 10
points of thickness spaced evenly around the vessel wall for
each section in a blinded manner.
Immunohistochemistry—The aortae and femoral arteries
frommicewere fixedwith 4%paraformaldehyde overnight, and
paraffin-embedded sections were prepared by the UNCHistol-
ogy Core facility. An immunohistochemistry paraffin protocol
provided by Abcam was followed, and the procedures were
described previously for Ki67 and DAPI staining (46–47). A
similar procedure was used for -actin staining. The Ki67-pos-
itive and total nuclei in awhole aortic ringwere quantified using
ImageJ (1.47N, National Institutes of Health) and expressed as
the percentage of total nuclei.
Formeasurement of aortic thickness, sections of aortae from
each group of mice were stained with hematoxylin and eosin.
Images were captured using an Olympus BX61 microscope.
Images were analyzed using ImageJ (1.47N, National Institutes
of Health) by measuring 10 points of thickness spaced evenly
around the vessel wall for each section in a blinded manner.
Total DAPI-stained nuclei in each aortic section from different
mice were counted.
Immunoprecipitation and Immunoblotting—The immuno-
precipitation and immunoblotting procedures were performed
as described previously (48). Immunoprecipitation was per-
formed by incubating 0.5 mg of cell lysate protein with 1 g of
anti-SHPS-1 antibody at 4 °C overnight. Immunoblotting was
performed using a dilution of 1:1000 for anti-pAKT (Ser-473),
pErk1/2, SM22, -actin, PCNA, and -actin antibodies and a
dilution 1:500 for anti-KLF-4, IRS-1, IRS-2, and myocardin
antibodies. The proteins were visualized using enhanced
chemiluminescence (Thermo Fisher Scientific).
Statistical Analysis—The results that are shown in all exper-
iments are representative of at least three independent experi-
ments and expressed as the mean  S.D. Analysis of variance
was applied for all data obtained from in vivo studies when
multiple points were compared. In addition, repeatedmeasures
analysis of variance was used where appropriate. p  0.05 was
considered statistically significant.
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